Post-Authorisation Registry of ELZONRIS (Tagraxofusp) in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Study identification

• EU PAS number:
  EUPAS1000001132
• Study ID:
  1000001132
• Official title and acronym:
  Post-Authorisation Registry of ELZONRIS (Tagraxofusp) in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
• DARWIN EU® study:
  No
• Study countries:
  Austria

  Germany

  Italy

  Switzerland
• Study description:
  Unique Protocol ID: STML-401-0521
• Study status:
  Ongoing

Research institutions and networks

No information provided.

Study timelines

Date when funding contract was signed

Actual:11/02/2021

Study start date

Actual:26/06/2024

Date of final study report

Planned:30/06/2031

Sources of funding

More details on funding

No information provided.

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 2 (specific obligation of marketing authorisation)